The Definitive Peptide Research Reference Guide — Compound Review

Home Compounds BPC-157 TB-500 CJC-1295 Ipamorelin GLP-1 GHK-Cu Epithalon NAD+ Comparisons BPC-157 vs TB-500 Sermorelin vs Ipamorelin Semaglutide vs Tirzepatide Guides GHK-Cu Guide GHRH Analogues Ipamorelin Guide Semaglutide Dosage BPC-157 Dosage Research Guides Joint Pain Weight Loss Longevity Shop Purgo Labs

CJC-1295 vs Sermorelin vs Ipamorelin

Three-way comparison of GH axis peptides: CJC-1295, Sermorelin, and Ipamorelin — covering receptor mechanisms, half-lives, and how to combine them for maximum GH stimulation.

Receptor Mechanism Comparison

CJC-1295 and Sermorelin: both act on GHRH receptors (GHRHR) to stimulate GH synthesis. Ipamorelin: acts on ghrelin receptors (GHS-R1a) to amplify GH pulse amplitude. Different receptors — combining a GHRH analogue with Ipamorelin produces synergistic GH release.

Combination Protocols

CJC-1295 (no DAC) + Ipamorelin: the most common combination — synergistic GH release, 2–5x greater than either alone. Sermorelin + Ipamorelin: similar synergy, lower cost. CJC-1295 (DAC) alone: sustained IGF-1 elevation without GHRP needed.

Summary Recommendation

For maximum GH axis stimulation: CJC-1295 (no DAC) + Ipamorelin, 2–3x daily. For cost-effectiveness: Sermorelin + Ipamorelin. For sustained IGF-1 elevation with minimal injection frequency: CJC-1295 with DAC, once weekly.